Sir,

With the recent publication of the MERTH study [@bib0005], trimethoprim/sulfamethoxazole (SXT) monotherapy will be used increasingly in the treatment of melioidosis during the eradication phase, and possibly as the only treatment for some mild infections. It is therefore important to know the prevalence of SXT resistance in *Burkholderia pseudomallei*. This is difficult to test in vitro, with disc diffusion testing overestimating resistance, and indistinct endpoints in all methods [@bib0010]. Even using the Etest method to estimate the minimum inhibitory concentration (MIC), SXT resistance rates as high as 24% in a year have occasionally been reported from Thailand [@bib0015]. Recent data from Northern Australia published in this journal [@bib0020] are consistent with our own experience in Southeast Asia and suggest that true resistance to SXT in *B. pseudomallei* is actually very rare.

As our own experience indicated a substantially lower prevalence of SXT resistance than the literature suggests, we reviewed routine data from our diagnostic laboratories in Laos (February 2003 to October 2012) and Cambodia (February 2006 to December 2012). Etest (bioMérieux, Basingstoke, UK) was performed according to the manufacturer\'s instructions on all isolates in Vientiane (Laos) and on all isolates that appeared non-susceptible by disc diffusion testing \[Clinical and Laboratory Standards Institute (CLSI) M02-A11 method; zone diameter \< 16 mm\] in Siem Reap (Cambodia), as previously recommended [@bib0015]. The sources of the strains tested are shown in [Table 1](#tbl0005){ref-type="table"}.

Of 769 sequential isolates, 99.2% (615/620) from Laos and 100% (149/149) from Cambodia were classified as susceptible to SXT according to CLSI criteria (trimethoprim MIC ≤ 2 mg/L). Three isolates had a trimethoprim MIC of 3 mg/L and two isolates had a trimethoprim MIC of 4 mg/L. The range of MICs is shown in [Fig. 1](#fig0005){ref-type="fig"}.

This confirms that primary resistance of *B. pseudomallei* to SXT is extremely uncommon and should rarely be a contraindication to SXT monotherapy. These results from Vientiane and Siem Reap closely mirror those of Crowe et al. in Darwin [@bib0020]. Although the CLSI currently only recommends broth microdilution testing for *B. pseudomallei* [@bib0025], many years of experience in melioidosis-endemic areas suggests that disc diffusion testing is reliable for all agents except SXT, for which Etest gives acceptable results. We think that the misleading data in the literature are due to the difficulty of interpreting endpoints in testing susceptibility of *B. pseudomallei* to SXT. We tried to follow the manufacturer\'s instructions and read the Etest at 80% inhibition, but this is a somewhat subjective endpoint. However, the really important thing that remains to be established is whether SXT MICs can predict the outcome of SXT monotherapy in melioidosis.
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###### 

Source of isolates.

                  Laos PDR   Cambodia
  --------------- ---------- ----------
  Blood culture   240        31
  Respiratory     126        2
  Pus/swab        228        115
  Fluid           26         1
  Total           620        149
